Journal of Clinical Oncology, Vol 10, 1810-1816, Copyright © 1992 by American Society of Clinical Oncology

ARTICLES

Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons

E Kodish, C Stocking, MJ Ratain, A Kohrman and M Siegler
Department of Pediatrics, University of Chicago Pritzker School of Medicine, IL.

PURPOSE: Phase I research trials assess the safety of agents never before administered to humans. In the field of oncology, this practice raises several important ethical questions. We examined the ethics of these trials by surveying phase I oncology investigators and institutional review board (IRB) chairpersons at major cancer research centers around the country. METHODS: Questionnaires were mailed to 78 investigators and 47 chairpersons to obtain their views on the ethical propriety of conducting phase I oncology research, and on institutional practice regarding these trials. The response rate was 68% in each group. RESULTS: The majority of each group reported that phase I oncology trials face no more scrutiny or resistance in their institution's IRB process than other research protocols. Nevertheless, IRB chairpersons were more likely than investigators to favor special procedural safeguards to protect subjects in phase I oncology trials. Nearly all respondents agreed that although actual medical benefit was very uncommon, most patients entered for a chance at a therapeutic effect. Investigators were more likely than chairpersons to report that patients obtained psychologic benefit from participation in phase I trials. CONCLUSION: Although individual IRB chairpersons and oncology investigators may have important differences of opinion concerning the ethics of phase I trials, these disagreements do not represent a widespread area of ethical conflict in clinical research.

This article has been cited by other articles:

				B. Lee, A. Lim, A. Lalvani, M. J. L. Descamps, R. Leonard, S. Nallamala, J. S. Lewis, R. C. Coombes, and J. Stebbing The clinical significance of radiologically detected silent pulmonary nodules in early breast cancer Ann. Onc., December 1, 2008; 19(12): 2001 - 2006. [Abstract] [Full Text] [PDF]

				A. Italiano, C. Massard, R. Bahleda, A.-L. Vataire, E. Deutsch, N. Magne, J.-P. Pignon, G. Vassal, J.-P. Armand, and J.-C. Soria Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy Ann. Onc., April 1, 2008; 19(4): 787 - 792. [Abstract] [Full Text] [PDF]

				M. Agulnik, A. M. Oza, G. R. Pond, and L. L. Siu Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents J. Clin. Oncol., October 20, 2006; 24(30): 4801 - 4807. [Abstract] [Full Text] [PDF]

				M. Agrawal, C. Grady, D. L. Fairclough, N. J. Meropol, K. Maynard, and E. J. Emanuel Patients' Decision-Making Process Regarding Participation in Phase I Oncology Research J. Clin. Oncol., September 20, 2006; 24(27): 4479 - 4484. [Abstract] [Full Text] [PDF]

				M. Markman "Therapeutic intent" in phase 1 oncology trials: a justifiable objective. Arch Intern Med, July 24, 2006; 166(14): 1446 - 1448. [Full Text] [PDF]

				J Kimmelman and N Palmour Therapeutic optimism in the consent forms of phase 1 gene transfer trials: an empirical analysis J. Med. Ethics, April 1, 2005; 31(4): 209 - 214. [Abstract] [Full Text] [PDF]

				E. Horstmann, M. S. McCabe, L. Grochow, S. Yamamoto, L. Rubinstein, T. Budd, D. Shoemaker, E. J. Emanuel, and C. Grady Risks and Benefits of Phase 1 Oncology Trials, 1991 through 2002 N. Engl. J. Med., March 3, 2005; 352(9): 895 - 904. [Abstract] [Full Text] [PDF]

				T. G. Roberts Jr, B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, and J. W. Clark Trends in the Risks and Benefits to Patients With Cancer Participating in Phase 1 Clinical Trials JAMA, November 3, 2004; 292(17): 2130 - 2140. [Abstract] [Full Text] [PDF]

				A. Chang Nurses' Perceptions of Phase I Clinical Trials in Pediatric Oncology: A Review of the Literature Journal of Pediatric Oncology Nursing, November 1, 2004; 21(6): 343 - 349. [Abstract] [PDF]

				M. Agrawal and E. J. Emanuel Ethics of Phase 1 Oncology Studies: Reexamining the Arguments and Data JAMA, August 27, 2003; 290(8): 1075 - 1082. [Abstract] [Full Text] [PDF]

				I. Byock and S. H. Miles Hospice Benefits and Phase I Cancer Trials Ann Intern Med, February 18, 2003; 138(4): 335 - 337. [Abstract] [Full Text] [PDF]

				S. Horng, E. J. Emanuel, B. Wilfond, J. Rackoff, K. Martz, and C. Grady Descriptions of Benefits and Risks in Consent Forms for Phase 1 Oncology Trials N. Engl. J. Med., December 26, 2002; 347(26): 2134 - 2140. [Abstract] [Full Text] [PDF]

				H. E. M. van Luijn, A. W. Musschenga, R. B. Keus, W. M. Robinson, and N. K. Aaronson Assessment of the risk/benefit ratio of phase II cancer clinical trials by Institutional Review Board (IRB) members Ann. Onc., August 1, 2002; 13(8): 1307 - 1313. [Abstract] [Full Text] [PDF]

				J. A. Deatrick, D. B. Angst, and C. Moore Parents' Views of their Children's Participation in Phase I Oncology Clinical Trials Journal of Pediatric Oncology Nursing, July 1, 2002; 19(4): 114 - 121. [Abstract] [PDF]

				K. C. Lintz, R. T. Penson, B. A. Chabner, S. Mack, and T. J. Lynch Jr. A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers Oncologist, June 1, 2002; 7(90002): 8 - 15. [Abstract] [Full Text] [PDF]

				S. Joffe, E. F. Cook, P. D. Cleary, J. W. Clark, and J. C. Weeks Quality of Informed Consent: a New Measure of Understanding Among Research Subjects J Natl Cancer Inst, January 17, 2001; 93(2): 139 - 147. [Abstract] [Full Text] [PDF]

				S. J L Edwards, R J Lilford, and J Hewison The ethics of randomised controlled trials from the perspectives of patients, the public, and healthcare professionals BMJ, October 31, 1998; 317(7167): 1209 - 1212. [Full Text]

				K. C. Lintz, R. T. Penson, B. A. Chabner, S. Mack, and T. J. Lynch A Staff Dialogue on Phase I Trials: Psychosocial Issues Faced by Patients, Their Families, and Caregivers Oncologist, October 1, 1998; 3(5): 357 - 364. [Abstract] [Full Text]